Worse Clinical Outcomes of Atrial Fibrillation in Patients with HFpEF Compared to HFrEF Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry

A multinational prospective cohort study performed by Barak Zafrir et al. and published in the European Heart Journal concluded that worse cardiovascular outcomes of atrial fibrillation (AF) were associated with heart failure with preserved ejection fraction (HFpEF) and heart failure with middle range ejection fraction (HFmrEF) but not associated with heart failure with reduced ejection fraction (HFrEF). Continue reading

SGLT-2 Inhibitors Associated with Lower Heart Failure Hospitalization Tighter glycemic control is not associated with lower risk of HF hospitalization: A Meta-Analysis

A new meta-analysis published in the Journal of American College of Cardiology showed that sodium glucose co-transporter (SGLT)-2 inhibitors are more effective than glucagon-like peptide (GLP)-1 agonists and dipeptidyl peptidase (DPP)-4 inhibitors in reducing the risk of Heart Failure (HF) hospitalization in patients with type 2 diabetes mellitus. Continue reading

Pulmonary Artery Denervation Improves Pulmonary HTN in Heart Failure Pulmonary Artery Denervation Significantly Increases 6-minute Walk Distance for Patients with Combined Pre- and Post-capillary Pulmonary Hypertension Associated with the Left Heart Failure: PADN-5 Study

The findings of the Pulmonary artery denervation (PADN) trial, presented at the TCT conference on Sept 23rd have shown that PADN is associated with significant improvements in hemodynamic and clinical outcomes including 6-minute walk distance (6MWD) and pulmonary vascular resistance (PVR) in patients with combined pre- and post-capillary pulmonary hypertension CpcPH. The results of this study were simultaneously published in JACC: Interventions. Continue reading

Landmark COAPT trial Demonstrates the Benefit of Transcatheter Mitral-Valve Repair Using MitraClip in Patients with Heart Failure TCT 2018: Findings of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) trial

The spectacular results of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) trial, presented at TCT 2018, show that transcatheter mitral valve approximation using the MitraClip, on a background of maximally tolerated guideline-directed medical therapy (GDMT) was superior to GDMT alone in the reduction of Heart Failure (HF) hospitalization and mortality in symptomatic HF patients with grade 3-4+ Mitral regurgitation (MR). These landmark findings were simultaneously published today in the New England Journal of Medicine. Continue reading

Coronary Microvascular Dysfunction: A Promising Therapeutic Target in Heart Failure with Preserved EF? PROMIS-HFpEF: Results from ESC 2018

PROMIS-HFpEF (PRevalence Of MIcrovascular dySfunction in Heart Failure with Preserved Ejection Fraction) is an echocardiographic trial showcasing a high prevalence of coronary microvascular dysfunction (CMD) in HFpEF and its association with systemic endothelial dysfunction (RHI, UACR) and markers of HF severity (NT-proBNP and RV dysfunction). The results of the trial were recently published in the European Heart Journal. Continue reading

Transcatheter Interatrial shunt device appears safe at 1 year for heart failure with preserved ejection fraction ESC 2018: REDUCE LAP HF-1, 1 year results from phase 2

The 1-year results of a phase 2, sham-controlled RCT have confirmed the safety of a transcatheter interatrial shunt device (IASD; Corvia Medical) with no significant cardiovascular or renal events as compared to those receiving sham control treatment. It has also confirmed the long-term patency of the device. The findings were presented at the ESC and have also been simultaneously published in JAMA Cardiology. Continue reading

Pre-PCI Impella Device Improves Outcome in Acute MI complicated by Cardiogenic Shock (AMICS)

A non-randomized study published in the American Heart Journal showed increased survival rates in patients with Impella device being used as the first support strategy for patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) when invasive hemodynamic monitoring was used, and at centers with higher Impella implantation volume. Continue reading

Tafamidis, A Real Hope for People with Transthyretin Cardiomyopathy?

On Thursday, March 29th, Pfizer announced positive topline results from ATTR-ACT trial of tafamidis in patients with transthyretin cardiomyopathy. According to Pfizer, “Tafamidis met its primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months. The preliminary safety data showed that tafamidis was generally well tolerated in this population and no new safety signals were identified”. Continue reading

Association of High-Sensitivity Cardiac Troponins (hs-cTn) and the Risk of New-onset Heart Failure

A recent study, published in the Journal of American College of Cardiology, concluded that there is a strong association of high sensitivity cardiac troponin (hs-cTn) with the risk of new-onset heart failure (HF), independent of population at risk, cardiovascular risk factors, and natriuretic peptide levels. Continue reading

ICON RELOADED: A New Future for NT-proBNP

A multicenter, international, North American study published in the Journal of the American College of Cardiology has indicated that N-terminal pro–B-type natriuretic peptide (NT-proBNP) testing may be valuable in the identification or exclusion of heart failure in emergency department patients with shortness of breath.

Continue reading

HeartMate 3: Magnetic Pump in Advanced Heart Failure

According to a new study published in the New England Journal of Medicine, a fully magnetically levitated centrifugal- flow pump has been found to be superior to a mechanical-bearing axial-flow pump in advanced heart failure patients in terms of survival free of disabling stroke or reoperation for removal in case of device malfunction.

Continue reading

MOMENTUM III: HeartMate III demonstrated 2-year Survival Benefit Compared to HeartMate II

Dr. Mehra and Dr. Gibson Discuss

Subscribe on iTunes or Google Play.

MOMENTUM III: HeartMate III demonstrated 2-year Survival Benefit Compared to HeartMate II Dr. Mehra and Dr. Gibson Discuss

ARISTOTLE: Digoxin in AFib with and without heart failure Dr. Renato Lopes and Dr. C. Michael Gibson Discuss

Silent MI: A Risk Factor for Heart Failure? Link between silent myocardial infarction and heart failure

In a recent analysis published in the Journal of the American College of Cardiology, a link between silent myocardial infarction and subsequent heart failure has been demonstrated, revealing a novel potential marker for heart failure. Continue reading

Transcatheter Inter-atrial Shunt Device for Treatment of HF

Dr. C. Michael Gibson discusses the trial findings with Dr. Sanjiv Shah at AHA 2017.

Transcatheter Inter-atrial Shunt Device for Treatment of HF Dr. Sanjiv Shah and Dr. C. Michael Gibson Discuss REDUCE LAP-HF